Dr. Michael Har-Noy Describes Amazing Results of Phase I/II Trial of AlloStim

10 Jan

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, an Israeli biotechnology company, reviews the results of a Phase I/II FDA-approved trial in which AlloStim, along with tumor cryoablation, was used to treat forty-two patients with various types of metastatic cancer.  Dr. Michael Har-Noy says these results will soon be published in a peer-reviewed journal.

This study was conducted in Carlsbad.  Dr. Michael Har-Noy indicated that forty-two patients, all heavily pre-treated with conventional therapy, were enrolled in the study.  All patients had a life expectancy of two months or less.  The average patient age was 61 years; 90% had prior surgery, 45% had prior radiation, and all had received prior chemotherapy.  The cancer types were 14 breast, 7 colorectal, 3 biliary, 3 squamous cell, 3 ovarian, 2 sarcoma, 2 esophageal, 2 pancreatic, 2 lung, 2 prostate, and 1 bladder.  Study patients had an average of 22.2 metastatic lesions; their ECOG (Eastern Cooperative Oncology Group) score averaged 2.2, indicating severe disability.

Dr. Michael Har-Noy said the study patients were first treated with 3 intradermal Allostim injections, followed by cryoablation of an accessible lesion and intravenous Allostim administration.  Cryoablation was done in the Carlsbad clinic for cutaneous or easily palpable tumors and, for deeper lesions, at a nearby radiology facility using computed tomographic (CT) guidance.

Dr. Michael Har-Noy noted that the forty-two patients had few adverse effects from the AlloStim.  The most commonly encountered reaction was a flu-like condition that began within the first few days after Allostim administration.  There were no severe reactions.

The mean survival of the patients was 163 days – three times the predicted survival in historic untreated controls.  Fully 20% of the study patients stayed in remission one full year after treatment!  Dr. Michael Har-Noy noted that some of these patients are still alive after four years.  This author does not know the longevity of each study patient, but as a group these results are far better than anything in the current medical literature.  Dr. Michael Har-Noy will soon publish this study in a peer-reviewed journal.  He says these results must be interpreted cautiously, as this was a non-controlled, non-randomized study.

Dr. Michael Har-Noy will soon conduct a Phase I/II trial of CRCL-AlloVaxTM, the company’s new ant-cancer vaccine, in Thailand.  Interested patients may register at www.immunocare.net.

Source: www.immunocare.net


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: